B of A Securities Maintains Buy on Janux Therapeutics, Lowers Price Target to $49
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Geoff Meacham maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $49.
B of A Securities analyst Geoff Meacham maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $49.